Analyst Note| Charles Gross |
After a periodic review of Aptar's valuation, we've raised our fair value estimate to $125 from $101 per share. The primary driver of the change is a more robust long-term growth outlook. Additionally, our near-term outlook now reflects faster growth in Aptar's pharmaceutical segment due to coronavirus vaccine tailwinds. Our narrow-moat rating remains unchanged.